Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Stephen How who wrote (724)	2/21/1998 2:32:00 AM
From: Keith J	Read Replies (2) \| Respond to of 1432

Two items regarding the post. One, who ever said Hextend is a blood substitute? Oh that's right, the shorts have said this many times. And as the longs have constantly repeated, Hextend is a blood volume expander, not a blood substitute. Gotta wonder either where this guy is getting his information from or how real his credentials are. Two, revolutionary? Who ever said Hextend was revolutionary? It's sort of like saying New Coke was revolutionary. Surely not Biotime. It is an improvement over current solutions, which everyone knows. Again, gotta wonder about where this person is getting his information from or how real his credentials are. KJ

To: Stephen How who wrote (724)	2/21/1998 3:20:00 AM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

This is what is known as a 'straw man' argument. One states what one hopes will be accepted as a premise in order to shoot it down. The fact is that shorts have been on this 'blood substitute' rag for quite a while now and when they pin that definition on Hextend then the rationale for a short interest is legitimate. The fact is that the short interest cannot argue against the efficacy of Hextend without either misrepresenting the nature of the product or misinterpreting the results of it. Period. Jim